leisure time -WSS

leisure time

author：explore 2025-10-01 12:55:02 - browse：64737

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： A new ‘biological computer' targets cancer while sparing healthy cells

focus

hotspot

WSS

Judge denies Trump's request for new trial in E. Jean Carroll case

Covid silver lining: Unprecedented look at human immune system

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Multiple sclerosis has subtypes with different best treatments: study

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

hotspot

leisure time

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

There’s a way to spot data fakery. All journals should be using it

Novavax promises a turnaround & Lilly roils the obesity market

Scientific mystery highlights the blind spots in genomics databases

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Researchers test human milk's ability to repair gut microbiome

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Virginia high school admissions case could be legal follow

5 dead in mass shooting on Caribbean island of St. Vincent: Police

leisure time

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Gut bacteria may contribute to kidney autoimmunity, study finds

Dementia risk linked to living in disadvantaged areas: Study

Sanders wants to replace patents with prizes for drug inventions

Four alarming medical procedures we’re glad history forgot

Study: Black kids more likely to die after surgery than white kids

focus

focus

hotspot

focus